Alliqua BioMedical, Inc. (NASDAQ:ALQA) had its price objective reduced by HC Wainwright from $2.50 to $1.50 in a research report released on Tuesday morning, StockTargetPrices.com reports. They currently have a buy rating on the stock.
A number of other brokerages have also commented on ALQA. Cowen and Company reaffirmed an outperform rating and set a $1.50 target price on shares of Alliqua BioMedical in a research report on Tuesday, April 11th. Chardan Capital reduced their target price on shares of Alliqua BioMedical from $2.00 to $1.25 and set a buy rating on the stock in a research report on Wednesday, March 8th. ValuEngine lowered shares of Alliqua BioMedical from a sell rating to a strong sell rating in a research report on Friday, June 2nd. Finally, Zacks Investment Research lowered shares of Alliqua BioMedical from a buy rating to a hold rating in a research report on Tuesday, April 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $1.19.
Shares of Alliqua BioMedical (ALQA) opened at 0.4297 on Tuesday. The firm’s 50-day moving average price is $0.37 and its 200 day moving average price is $0.50. Alliqua BioMedical has a 52-week low of $0.32 and a 52-week high of $1.29. The company’s market capitalization is $19.76 million.
Alliqua BioMedical (NASDAQ:ALQA) last issued its earnings results on Tuesday, May 9th. The company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.04. The company had revenue of $4.59 million for the quarter, compared to analysts’ expectations of $4.62 million. Alliqua BioMedical had a negative return on equity of 75.87% and a negative net margin of 145.99%. The business’s revenue was up 15.9% compared to the same quarter last year. During the same period last year, the business posted ($0.25) earnings per share. On average, equities analysts forecast that Alliqua BioMedical will post ($0.62) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Alliqua BioMedical, Inc. (NASDAQ:ALQA) PT Lowered to $1.50 at HC Wainwright” was originally reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.wkrb13.com/markets/2284889/alliqua-biomedical-inc-nasdaqalqa-pt-lowered-to-1-50-at-hc-wainwright.html.
Several institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC increased its position in Alliqua BioMedical by 120.3% in the first quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock worth $2,136,000 after buying an additional 2,312,000 shares in the last quarter. Sabby Management LLC increased its position in Alliqua BioMedical by 93.7% in the first quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock worth $1,076,000 after buying an additional 1,030,652 shares in the last quarter. KCG Holdings Inc. increased its position in Alliqua BioMedical by 777.7% in the first quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock worth $265,000 after buying an additional 465,256 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Alliqua BioMedical by 54.2% in the first quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock worth $319,000 after buying an additional 222,400 shares in the last quarter. Hedge funds and other institutional investors own 26.19% of the company’s stock.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2284889/alliqua-biomedical-inc-nasdaqalqa-pt-lowered-to-1-50-at-hc-wainwright.html
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.